18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment

Inclusion Criteria:

- History of histologically confirmed adenocarcinoma of the prostate post
curative-intent local treatment (radical prostatectomy, local radiotherapy,
brachytherapy).

- Suspicion of recurrent prostate carcinoma after previous presumed definitive therapy
for organ confined disease defined as :

- Post prostatectomy: Detectable or rising PSA level that is >0.2 ng/mL with a second
confirmatory level of >0.2 ng/mL

- Post non-prostatectomy: PSA rise ≥ 2ng/mL over nadir

- Negative or equivocal findings on standard-of-care imaging for restaging of disease in
the previous 60 days consisting of: Whole-body 99mTc bone scintigraphy or NaF PET-CT;
and either CT or MRI of the pelvis (or the abdomen and pelvis).

- Being considered for salvage therapy

- Any non-surgical local treatment such as previous cryotherapy, external beam
radiation, or HiFU (Ultrasound) must have occurred at least 1 year in the past.

- Previous brachytherapy treatment will have occurred at least 2 years in the past

- Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

- Ongoing treatment with any systemic therapy intended for the treatment of prostate
cancer (e.g., antiandrogen or LHRH agonist or antagonist)

- Androgen deprivation therapy (ADT) in the past 3 months

- History of bilateral orchidectomy

- Inability to tolerate 18F-fluciclovine PET/CT